Department of Surgery, Leiden University Medical Center, Leiden, Netherlands.
Molecular Imaging Program at Stanford (MIPS), Stanford School of Medicine, Palo Alto, CA, USA.
Nat Rev Clin Oncol. 2022 Jan;19(1):9-22. doi: 10.1038/s41571-021-00548-3. Epub 2021 Sep 7.
Fluorescence-guided surgery using tumour-targeted imaging agents has emerged over the past decade as a promising and effective method of intraoperative cancer detection. An impressive number of fluorescently labelled antibodies, peptides, particles and other molecules related to cancer hallmarks have been developed for the illumination of target lesions. New approaches are being implemented to translate these imaging agents into the clinic, although only a few have made it past early-phase clinical trials. For this translational process to succeed, target selection, imaging agents and their related detection systems and clinical implementation have to operate in perfect harmony to enable real-time intraoperative visualization that can benefit patients. Herein, we review key aspects of this imaging cascade and focus on imaging approaches and methods that have helped to shed new light onto the field of intraoperative fluorescence-guided cancer surgery with the singular goal of improving patient outcomes.
在过去十年中，使用肿瘤靶向成像剂的荧光引导手术已成为一种有前景且有效的术中癌症检测方法。为了照亮目标病变，人们已经开发出了数量可观的与癌症特征相关的荧光标记抗体、肽、颗粒及其他分子。尽管只有少数成像剂通过了早期临床试验，但仍在采用新方法将这些成像剂转化应用于临床。要使这一转化过程取得成功，靶点选择、成像剂及其相关检测系统以及临床应用必须完美配合，以实现实时术中可视化，从而使患者受益。在此，我们回顾这一成像流程的关键方面，并聚焦于那些有助于为术中荧光引导癌症手术领域带来新见解的成像方法，其唯一目标是改善患者预后。
